NATIONAL COMMUNITY PHARMACISTS ASSOCIATION for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 22, 2024 | $340,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Mar 11, 2025 | $340,000 | Yes |
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Alcohol and Drug Abuse ALC
S. 2666, the E-Prescribing Parity for Controlled Substances Act; Remote Prescribing of Controlled Substances & Dispensing of Controlled Substances;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN New | — |
Medicare/Medicaid MMM
H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024 Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement; Comments to CMS on the implementation of Medicare Part D vaccine coverage under the Inflation Reduction Act (IRA; P.L. 117-169); Comments to CMMI on the Importance of Implementing Reasonable Reimbursement Guardrails for Pharmacies in the Medicare $2 Drug List Model based on the Executive Order on Lowering Prescription Drug Costs for Americans; Comments to HHS and CMS on 2024 NADAC Methodology Changes; Comment on "Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027.";
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN New | — |
Pharmacy PHA
H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 2679, the Pharmacy Benefits Manager Accountability Act; H.R. 3008, the Drug Shortage Prevention Act; S. 1339, the Pharmacy Benefits Manager Reform Act; S. 1542 / H.R. 6283, the Delinking Revenue from Unfair Gouging Act; H.R. 1173, the Patients Right to Know Their Medication Act of 2023; Proposed rule for Medication Guides: Patient Medication Information (Docket No. FDA-2019-N-5959); Implementation of Public Law 113-54, the Drug Quality and Security Act; Draft Guidance for Industry, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act, (Docket No. FDA-2015-D-3517); H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act" (Docket No. FDA-2023-N-4806); Request for Information on Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024; H.R.2882, the Further Consolidated Appropriations Act, 2024; Comments on implementation and enforcement of recent changes to USP Chapter <797>, regarding the Compounded Sterile Preparations (CSPs) in Category 3 to the FDA; Comments on "Agency Information Collection Activities; Proposed Collection; Comment Request; Proposed Small Dispensers Assessment Under the Drug Supply Chain Security Act" [Docket No.FDA-2024-N-0668]; Comments on " Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act"[Docket No. FDA-2023-N-0061];
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN New | — |
Taxation/Internal Revenue Code TAX
H.R. 4794, the Dietary Supplement Access Act; H.R.8147, Repealing Big Brother Overreach Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN New | — |
Labor Issues/Antitrust/Workplace LBR
S. 127, the PBM Transparency Act; S. 113, the Prescription Pricing for the People Act; Request for Information on "Consolidation in Health Care Markets [Docket No. ATR 102]";
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN New | — |
Defense DEF
TRICARE pharmacy network changes; H.R. 2670, National Defense Authorization Act for Fiscal Year 2024; H.R. 4638, National Defense Authorization Act for Fiscal Year 2025;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN New | — |
Budget/Appropriations BUD
FY24 appropriations language request to fund FTC enforcement of the Robinson-Patman Act; FY24 appropriations report language to address TRICARE pharmacy network; Labor, Health and Human Services, Education, and Related Agencies Appropriations Bill, FY 2025;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN New | — |
Telecommunications TEC
Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.